IRadimed Corporation (IRMD): Accelerating with Solid Capital Return

2 weeks ago 9

Soumya Eswaran

Mon, January 19, 2026 astatine 7:50 AM CST 3 min read

Riverwater Partners, an concern absorption company, released its “Micro Opportunities Strategy” Q4 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Both Q4 and the afloat twelvemonth 2025 were challenging for the strategy, which struggled to lucifer the benchmark show successful Q4 and FY2025. The underweight vulnerability successful speculative areas of the marketplace led to the underperformance successful the 2nd fractional of the year. Low-quality stocks with mediocre fundamentals outperformed the marketplace successful the year. The strategy’s accent connected high-quality stocks lagged down the broader marketplace trends. Heading to 2026, the Strategy focuses connected micro-cap companies with broader income and maturation trajectories and believes that the low-quality banal marketplace rallies volition beryllium short-lived. In addition, you tin cheque the fund’s apical 5 holdings to find its champion picks for 2025.

In the fourth-quarter 2025 capitalist letter, Riverwater Partners Micro Opportunities Strategy highlighted IRADIMED CORPORATION (NASDAQ:IRMD) arsenic its apical show contributor. Headquartered successful Orlando, Florida, IRADIMED CORPORATION (NASDAQ:IRMD) is simply a magnetic resonance imaging (MRI) compatible aesculapian instrumentality manufacturer. The one-month instrumentality for IRADIMED CORPORATION (NASDAQ:IRMD) was 5.01%, and its shares gained 72.38% implicit the past 52 weeks. On December 15, 2025, IRADIMED CORPORATION (NASDAQ:IRMD) banal closed astatine $102.00 per share, with a marketplace capitalization of $1.244 billion.

Riverwater Partners Micro Opportunities Strategy stated the pursuing regarding IRADIMED CORPORATION (NASDAQ:IRMD) successful its 4th fourth 2025 capitalist letter:

"IRADIMED CORPORATION (NASDAQ:IRMD) was our apical contributor for some the 4th and the afloat year. The MRI-compatible aesculapian instrumentality institution rallied astir 38% successful the 4th fourth and gained astir 80% for the year.

IRADIMED CORPORATION (NASDAQ:IRMD) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 14 hedge money portfolios held IRADIMED CORPORATION (NASDAQ:IRMD) astatine the extremity of the 3rd quarter, which was 13 successful the erstwhile quarter. In Q3 2025, IRADIMED CORPORATION (NASDAQ:IRMD) reported record revenue of $21.2 million, marking an summation of 16% from Q3 2024. While we admit the imaginable of IRADIMED CORPORATION (NASDAQ:IRMD) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.